Navigation Links
Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants
Date:4/18/2011

MADISON, N.J., April 18, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of its AccuType® IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection. Quest Diagnostics is now offering the test to physicians and other healthcare providers in the U.S. and to pharmaceutical companies for use in clinical trials research.

The test was developed through a global non-exclusive license agreement under which Schering Corporation, a Merck affiliate, licensed certain patent rights claiming Interleukin (IL) 28B genetic markers to Quest Diagnostics. These genetic markers have been shown to provide an indicator of potential response to peginterferon alpha-based therapy for HCV. Additional terms were not disclosed.

"Our AccuType IL28B test will give physicians greater insights for treating individual patients infected with the most common form of HCV using standard antiviral therapies," said Rick L. Pesano, M.D., Ph.D., medical director, infectious diseases, Quest Diagnostics. "AccuType IL28B testing will also help physicians consider alternative therapies, which in the future may include HCV protease inhibitors."

Combination interferon-ribavirin therapy administered over several months is considered standard of care in treating HCV, although experimental HCV protease inhibitors are now under priority review by the U.S. Food and Drug Administration.(1),(2)  Side effects, such as fatigue, depression and nausea, affect the majority of patients, and an estimated 10% to 14% of people discontinue therapy.(3),(4) Moreover, as many as one in two patients fail to eradicate the virus, as indicated by blood tests, after a full course of therapy.(5)

A
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Roper Industries, Inc. (NYSE: ROP) ... a definitive agreement to acquire Northern Digital, Inc., ... medical applications.  Northern Digital will become part of ... Ontario, Canada, Northern Digital provides optical and electromagnetic ...
... Conn., May 10, 2011 Biodel Inc. (Nasdaq: ... initiated a pump trial of Biodel,s two ultra-rapid-acting formulations ... BIOD-105 and BIOD-107, are designed to result in more ... analogs.  This study is designed as a double blinded, ...
Cached Medicine Technology:Roper Industries to Acquire Northern Digital, Inc. 2Roper Industries to Acquire Northern Digital, Inc. 3Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps 2Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps 3Independent Investigator Initiates Phase 1 Study of Biodel's Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps 4
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... industry trend and boost enrollmentsDOVER, N.H., April 15 /PRNewswire/ ... and fitness clubs continue their own struggle to stay ... the fastest growing operator of full-size fitness clubs in ... advertising campaign that produced new memberships totaling in the ...
... Medical Center ... the prevention of pressure ulcers OAK BROOK, Ill. and BATESVILLE, ... B.C., M.S.N, C.W.O.C.N., of Beth Israel Medical Center, New York, ... a role launched this year by Joint Commission Resources (JCR) ...
... new series of national public service advertisements designed to ... by knowing and asking appropriate questions when visiting their ... U.S. Department of Health and Human Services, Agency for ... actress and health advocate Fran Drescher.The new "Questions" PSAs, ...
... Efforts to Assist Hospitals Managing Merger of Economic ... RWD Technologies, LLC (RWD), a global company ... solutions, today announced a multimillion-dollar investment in its ... engagement of various stakeholders about process improvements that ...
... WHEN: Thursday, April 16, 2009 at 11 a.m. EDT ... complimentary registration , SPEAKERS: ... Frost & Sullivan , Daniel Shipp, President, ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , , ...
... drug abusers , , WEDNESDAY, April 15 (HealthDay News) -- ... its kind, methamphetamine use among pregnant women has been ... exposed to the drug in the womb. , Whether ... seen, one expert said. , "If we accept the ...
Cached Medicine News:Health News:Despite Ailing Economy, Planet Fitness Thrives 2Health News:JCR and Hill-Rom Name First Nurse Scholar-in-Residence 2Health News:JCR and Hill-Rom Name First Nurse Scholar-in-Residence 3Health News:AHRQ and Ad Council Encourage Consumers to Ask Questions and Get More Involved in Their Health Care 2Health News:AHRQ and Ad Council Encourage Consumers to Ask Questions and Get More Involved in Their Health Care 3Health News:RWD Announces Investments In Growing Health Care Practice 2Health News:RWD Announces Investments In Growing Health Care Practice 3Health News:RWD Announces Investments In Growing Health Care Practice 4Health News:Frost & Sullivan and International Safety Equipment Association (ISEA) Present a Webinar on the Economy: 'Personal Protective Equipment Industry - Immune to Global Slowdown?' 2Health News:Frost & Sullivan and International Safety Equipment Association (ISEA) Present a Webinar on the Economy: 'Personal Protective Equipment Industry - Immune to Global Slowdown?' 3Health News:Fetal Exposure to Methamphetamine May Harm Child's Brain 2
... electrophysiology system is the Espion. This is an ... wide variety of stimulators for different types of ... ,The Espion system was designed from the ... standard clinical visual function tests, ERG, VEP, PERG, ...
... heart of the Espion2 Electrophysiology system. The ... chassis, real-time DSP, USB control, an isolated ... amplifiers. The E2 connects to any Windows ... standard wi-fi Ethernet. The E2 includes easy ...
... II-i series is a wheelchair accessible, computerized ... field. ,By using SITA, the expert operating ... up to 70%. ,A patented aspherically shaped ... increase patient comfort while testing out to ...
... AAA Endoprosthesis is an innovative device designed ... for patients with abdominal aortic aneurysms (AAA). ... bifurcated graft with an outer self-expanding Nitinol ... and material durability. The function of the ...
Medicine Products: